Join
Live feed
·
PRReleasevia Quantisnow
Nuvectis Pharma Inc. logo

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

ByQuantisnow·Wall Street's wire, on your screen.
NVCT· Nuvectis Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NVCT (Nuvectis Pharma Inc.) and more on Quantisnow.